Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API
Use of the cocrystal increased the aqueous dissolution rate by 18 times as compared to the homomeric crystalline form of the drug and showed that it is unique regarding thermal, spectroscopic, X-ray, and dissolution properties.
An iterative model for in vitro laboratory assessment of tamper deterrent formulations.
(362) In vitro assessment of the effects of alcohol on the release rate of extended-release opioid formulations (Hysingla® ER, OxyContin® and Zohydro® ER).
Improved global response outcome after intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder
Intradetrusor-injected AMDC as a treatment for UAB was successfully completed in a 20-patient trial without serious adverse event and with signal of efficacy, and cellular therapy may be a promising novel treatment for catheter-dependent chronic urinary retention.
Re: Kim N, Delport E, Cucuzzella T, Marley J, Pruitt C. Is sedation indicated before spinal injections? Spine 2007;32:E748-E52.
An important error is written to advise the author of an important error in the paper by Çelik and Kara that shaving the incision site results in statistically significantly more infections.
Comment on Mayock SP, Saim S, Fleming AB. In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations
This study describes the release-rate profiles following in-vitro dissolution of intact and crushed Xtampza ER capsules vs. OxyContin tablets, which are two extended-release ER oxycodone formulations with US Food and Drug Administration (FDA)-approved labeling for physicochemical abuse-deterrent properties (ADP).
In response to Gudin et al. — Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties
- N. Crudele, J. Giordano, R. Kapil, Amarita S. Randhawa
- Medicine, BiologyPain medicine
- 15 December 2016
It is likely that the ability to retain ER features following manipulation will make it less attractive to abusers compared to existing ADFs, and this statement is misleading as it suggests Xtampza can be dosed with or without regard to food, when such is not the case.